I'm LongbridgeAI, I can summarize articles.Pomerantz LLP is investigating ARS Pharmaceuticals (NASDAQ: SPRY) for potential securities fraud following a June 24, 2026 press release stating that its product neffy failed to secure commercial insurance coverage. This news caused the stock price to drop 23.91% to $8.02 on June 25, 2026. Investors are advised to contact Danielle Peyton at Pomerantz LLP regarding the investigation.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether ARS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On June 24, 2026, ARS issued a press release "provid[ing] an update on payer access for neffy® (epinephrine nasal spray)", disclosing that neffy had failed to secure commercial insurance coverage.
On this news, ARS's stock price fell $2.52 per share, or 23.91%, to close at $8.02 per share on June 25, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
